Haris Ali, MD, City of Hope

Articles

REACH3 Trial: Approval of Ruxolitinib in Chronic GVHD

April 22nd 2022

Comprehensive insight on the design and results of REACH3, which analyzed ruxolitinib as second-line therapy for chronic graft-vs-host disease.

Mechanism of Action of Ruxolitinib

April 15th 2022

In the context of chronic graft-vs-host disease, expert Yi-Bin Chen, MD, provides an overview of ruxolitinib’s mechanism of action.

Belumosudil’s Approval and Use in Chronic Graft-Vs-Host Disease

April 15th 2022

Haris Ali, MD, shares insight on belumosudil, a ROCK2 inhibitor approved in the management of chronic graft-vs-host disease.

Ibrutinib’s Approval and Use in Chronic Graft-Versus-Host Disease

April 8th 2022

Corey Cutler, MD, MPH, FRCPC, breaks down the mechanism of action and FDA approval of ibrutinib, a BTK inhibitor, in chronic graft-versus-host disease.

Identifying and Managing Steroid-Refractory Chronic GVHD

April 8th 2022

Expert perspectives on optimal treatment strategies for patients who develop steroid-refractory chronic graft-versus-host disease.

Defining Steroid-Refractory and Steroid-Dependent GVHD

April 1st 2022

Yi-Bin Chen, MD outlines the definition of steroid-refractory vs steroid-dependent graft-vs-host disease.

Frontline Treatment Options for Chronic GVHD

April 1st 2022

A comprehensive breakdown of frontline treatment strategies for patients with newly diagnosed chronic graft-vs-host disease.

Acute vs Chronic GVHD: Identification and Stratification

March 25th 2022

Insight on the identification of acute versus chronic graft-versus-host disease, including best diagnostic and risk stratification practices.

Background on Graft-vs-Host Disease: Risk Factors and Prevention

March 25th 2022

Corey Cutler, MD, MPH, FRCPC, provides an overview of graft-versus-host disease, followed by insight on standard disease prevention practices.

Unmet Needs in GVHD

May 4th 2021

Challenges and unmet needs in steroid-refractory GVHD and advice to community oncologists for the optimal management of disease.

Emerging Therapies for Acute and Chronic GVHD

May 4th 2021

Novel agents in the pipeline for the treatment of acute and chronic GVHD are discussed.

Treatment for Steroid-Refractory Chronic GVHD

April 27th 2021

A review of treatment options for patients with chronic GVHD who don’t respond to steroid therapy and preliminary findings from the phase 3 REACH3 trial.

Treatment for Steroid-Refractory Acute GVHD

April 27th 2021

Defining steroid-refractory acute GVHD, treatment options for patients who don’t respond to steroid therapy, and a review of the REACH2 trial.

Initial Therapy in GVHD

April 20th 2021

Experts in hematology-oncology share insights on approaching initial treatment and the treatment goals for acute and chronic GVHD.

Role of GVHD Prophylaxis

April 20th 2021

A discussion on the role of prophylactic therapy for patients after transplant as well as available options for GVHD prophylaxis.

Diagnosis of Acute and Chronic GVHD

April 13th 2021

Hematologist-oncologists review the typical presentation and diagnosis of acute and chronic GVHD and define how severity is classified.

Overview of Graft-Versus-Host Disease

April 13th 2021

Corey S. Cutler, MD, MPH, FRCPC; Yi-Bin Chen, MD; and Haris Ali, MD, provide insight on the nature of graft-vs-host disease (GVHD) and common risk factors for acute and chronic GVHD.